// App-Quantinova.ai

2144 : Inhibition of Immune Cell Subsets Is Differentially Affected By Dasatinib Dosage in Patients with Chronic Phase CML

Researchers

Presenter

  • Patrick Harrington

Principal Investigators

  • Richard Dillon

  • Deepti H. Radia

  • Donal P. McLornan

  • Philippe Rousselot

  • Katayoun Rezvani

  • Shahram Kordasti

  • Claire Harrison

  • Hugues de Lavallade

Medical Centers

  • School of Cancer and Pharmaceutical Science, King's College London, London, UK UK

  • Department of Medical Oncology, Guys and St Thomas NHS Foundation Trust, London, United Kingdom

  • Medical and Molecular Genetics, Kings College, London, London, United Kingdom

  • Department of Clinical Haematology, Guy's & St Thomas' NHS Foundation Trust, London, ENG, United Kingdom

  • Centre Hospitalier De Versailles Le Chesnay France

  • Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX

  • Systems Cancer Immunology, Comprehensive Cancer Centre, Kings's College Hospital, London, United Kingdom

  • Department of Haematology, Guys and St Thomas Hospitals NHS Trust, London, United Kingdom

  • Department of Urology, King's College Hospital NHS Foundation Trust, London, United Kingdom

Locations

  • United Kingdom

  • France

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • Natural Killer cells

  • Breakpoint Cluster Region

  • Cluster of Differentiation 4

  • Cluster of differentiation 8A

  • Interleukin-2

  • Regulatory T cells

Drug/Treatment

  • Nilotinib

  • dasatinib

  • Imatinib

  • IkT001

  • OKT3

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved